当前位置: 首页 >> 检索结果
3381. Furosemide-induced natriuresis is augmented by ultra-low-dose captopril but not by standard doses of captopril in chronic heart failure.
Ten chronic heart failure patients were studied on three occasions in randomized double-blind fashion to compare the acute hemodynamic, neurohormonal, and renal sodium-handling responses to 1 mg captopril versus 25 mg captopril, both in the absence of loop diuretic therapy and during furosemide-stimulated natriuresis.
3382. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of left ventricular dysfunction in patients with heart failure. SOLVD Investigators.
作者: M A Konstam.;M F Rousseau.;M W Kronenberg.;J E Udelson.;J Melin.;D Stewart.;N Dolan.;T R Edens.;S Ahn.;D Kinan.
来源: Circulation. 1992年86卷2期431-8页
In patients with heart failure, activation of the renin-angiotensin system is common and has been postulated to provide a stimulus for further left ventricular (LV) structural and functional derangement. We tested the hypothesis that chronic administration of the angiotensin converting enzyme (ACE) inhibitor enalapril prevents or reverses LV dilatation and systolic dysfunction among patients with depressed ejection fraction (EF) and symptomatic heart failure.
3383. Myocardial viability in patients with Q wave myocardial infarction and no residual ischemia.
作者: G Montalescot.;M Faraggi.;G Drobinski.;O Messian.;J Evans.;Y Grosgogeat.;D Thomas.
来源: Circulation. 1992年86卷1期47-55页
Coronary revascularization in patients with persistent angina after myocardial infarction reduces the incidence of recurrent angina pectoris and myocardial infarction and improves left ventricular function. The results of revascularization after a Q wave myocardial infarction when there is no residual ischemia may depend on myocardial viability.
3384. Thrombolysis in patients with unstable angina improves the angiographic but not the clinical outcome. Results of UNASEM, a multicenter, randomized, placebo-controlled, clinical trial with anistreplase.
作者: F W Bär.;F W Verheugt.;J Col.;P Materne.;J P Monassier.;P G Geslin.;J Metzger.;P Raynaud.;J Foucault.;C de Zwaan.
来源: Circulation. 1992年86卷1期131-7页
The value of thrombolytic therapy in unstable angina is unclear.
3385. Recombinant tissue-type plasminogen activator and immediate angioplasty in acute myocardial infarction. One-year follow-up. The European Cooperative Study Group.
作者: A E Arnold.;M L Simoons.;F Van de Werf.;D P de Bono.;J Lubsen.;J G Tijssen.;P W Serruys.;M Verstraete.
来源: Circulation. 1992年86卷1期111-20页
The European Cooperative Study Group conducted two randomized trials in patients with suspected myocardial infarction to assess the effect of 100 mg single-chain recombinant tissue-type plasminogen activator (rt-PA, alteplase) on enzymatic infarct size, left ventricular function, morbidity and mortality relative to placebo (alteplase/placebo trial) and to assess the effect of immediate percutaneous transluminal coronary angioplasty (PTCA) in addition to alteplase (alteplase/PTCA trial). One-year follow-up results are reported.
3386. Regular physical exercise and low-fat diet. Effects on progression of coronary artery disease.
作者: G Schuler.;R Hambrecht.;G Schlierf.;J Niebauer.;K Hauer.;J Neumann.;E Hoberg.;A Drinkmann.;F Bacher.;M Grunze.
来源: Circulation. 1992年86卷1期1-11页
Significant regression of coronary and femoral atherosclerotic lesions has been documented by angiographic studies using aggressive lipid-lowering treatment. This study tested the applicability and effects of intensive physical exercise and low-fat diet on coronary morphology and myocardial perfusion in nonselected patients with stable angina pectoris.
3387. Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Multicenter European Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MERCATOR) Study Group.
来源: Circulation. 1992年86卷1期100-10页
Cilazapril is a novel angiotensin converting enzyme inhibitor with antiproliferative effects in the rat model after balloon injury.
3388. Controlled trial of physical training in chronic heart failure. Exercise performance, hemodynamics, ventilation, and autonomic function.
作者: A J Coats.;S Adamopoulos.;A Radaelli.;A McCance.;T E Meyer.;L Bernardi.;P L Solda.;P Davey.;O Ormerod.;C Forfar.
来源: Circulation. 1992年85卷6期2119-31页
Many secondary abnormalities in chronic heart failure (CHF) may reflect physical deconditioning. There has been no prospective, controlled study of the effects of physical training on hemodynamics and autonomic function in CHF.
3389. A randomized trial of late reperfusion therapy for acute myocardial infarction. Thrombolysis and Angioplasty in Myocardial Infarction-6 Study Group.
作者: E J Topol.;R M Califf.;M Vandormael.;C L Grines.;B S George.;M L Sanz.;T Wall.;M O'Brien.;M Schwaiger.;F V Aguirre.
来源: Circulation. 1992年85卷6期2090-9页
Experimental and observational clinical studies of acute coronary occlusion have suggested that late reperfusion prevents infarct expansion and facilitates myocardial healing. The purpose of this trial was to assess whether infarct vessel patency could be achieved in late-entry patients and what benefit, if any, can be demonstrated.
3390. Hypolipidemic effect of type Ia antiarrhythmic agents in postinfarction patients.
Elevated levels of cholesterol and apoprotein B (apo B), the essential carrier protein for low density lipoprotein, are major lipid risk factors for premature coronary disease. Antiarrhythmic agents are frequently prescribed to patients with coronary heart disease and associated cardiac arrhythmias. As part of another study, we retrospectively investigated the effect of antiarrhythmic agents on blood lipids.
3391. Acute reduction of lipoprotein(a) by tissue-type plasminogen activator.
作者: R A Hegele.;M R Freeman.;A Langer.;P W Connelly.;P W Armstrong.
来源: Circulation. 1992年85卷6期2034-8页
Lipoprotein(a) [Lp(a)] is a low density lipoprotein-like particle whose apolipoprotein B (apo B) moiety is disulfide-linked to apo(a), a plasminogen-like inhibitor of fibrinolysis in vitro. We hypothesized that plasma concentrations of Lp(a) are acutely affected by intravenous tissue-type plasminogen activator (t-PA).
3392. Prevalence of circadian variations and spontaneous variability of cardiac disorders and ECG changes suggestive of myocardial ischemia in systemic arterial hypertension.
作者: M Zehender.;T Meinertz.;S Hohnloser.;A Geibel.;U Gerisch.;M Olschewski.;H Just.
来源: Circulation. 1992年85卷5期1808-15页
Systemic hypertension is a well-known risk factor for coronary artery disease and sudden cardiac death. Recent interest focused on the presence of malignant ventricular arrhythmias (VA) and myocardial ischemia in hypertensive patients and provided a potential link for fatal tachyarrhythmic events.
3394. Intermittent ST depression and mortality after myocardial infarction.
作者: W Ruberman.;R Crow.;C R Rosenberg.;P M Rautaharju.;R E Shore.;B S Pasternack.
来源: Circulation. 1992年85卷4期1440-6页
We conducted a case-control analysis to determine the contribution made to mortality by intermittent ST depression (STD) among patients enrolled in the already completed Beta Blocker Heart Attack Trial.
3395. Expanded Clinical Evaluation of Lovastatin (EXCEL) study results. Effect of patient characteristics on lovastatin-induced changes in plasma concentrations of lipids and lipoproteins.
作者: C L Shear.;F A Franklin.;S Stinnett.;D P Hurley.;R H Bradford.;A N Chremos.;D T Nash.;A Langendorfer.
来源: Circulation. 1992年85卷4期1293-303页
Lovastatin produces consistent dose-related reductions in plasma levels of low density lipoprotein (LDL) cholesterol along with variable decreases in triglycerides and increases in high density lipoprotein (HDL) cholesterol. Patient characteristics from the Expanded Clinical Evaluation of Lovastatin (EXCEL) study were examined to determine their association with the magnitude of lovastatin-induced changes in these lipids and lipoproteins.
3396. Predictors of early morbidity and mortality after thrombolytic therapy of acute myocardial infarction. Analyses of patient subgroups in the Thrombolysis in Myocardial Infarction (TIMI) trial, phase II.
作者: H S Mueller.;L S Cohen.;E Braunwald.;S Forman.;F Feit.;A Ross.;M Schweiger.;H Cabin.;R Davison.;D Miller.
来源: Circulation. 1992年85卷4期1254-64页
Thrombolysis has altered treatment of acute myocardial infarction (AMI). Therefore, reevaluation of predictors of outcome and treatment strategies is appropriate.
3397. Randomized trial of subcutaneous low-molecular-weight heparin CY 216 (Fraxiparine) compared with intravenous unfractionated heparin in the curative treatment of submassive pulmonary embolism. A dose-ranging study.
作者: C Théry.;G Simonneau.;G Meyer.;O Hélénon.;F Bridey.;C Armagnac.;P d'Azemar.;J P Coquart.
来源: Circulation. 1992年85卷4期1380-9页
We compared the efficacy and safety of different dosages of a low-molecular-weight heparin, CY 216 D (Fraxiparine), in the treatment of submassive pulmonary embolism with unfractionated heparin in a prospective, randomized, dose-finding study.
3398. Double-blind, randomized, controlled trial of fish oil supplements in prevention of recurrence of stenosis after coronary angioplasty.
Previous studies suggest that recurrence of coronary stenosis after percutaneous transluminal coronary angioplasty (PTCA) might be prevented with dietary supplements rich in omega-3 fatty acids. The purpose of the present study was to evaluate this hypothesis. In addition, the relation between usual dietary consumption of omega-3 fatty acids and restenosis was assessed.
3399. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group.
作者: S H Kubo.;S Gollub.;R Bourge.;P Rahko.;F Cobb.;M Jessup.;S Brozena.;M Brodsky.;P Kirlin.;J Shanes.
来源: Circulation. 1992年85卷3期942-9页
This multicenter trial was conducted to determine the efficacy and safety of pimobendan, an inotropic agent with calcium-sensitizing properties and activity as a phosphodiesterase inhibitor, in patients with heart failure.
3400. Plasma fibrinopeptide A levels in patients with acute myocardial infarction treated with alteplase. Correlation with concomitant heparin, coronary artery patency, and recurrent ischemia. The European Cooperative Study Group.
作者: H J Rapold.;D de Bono.;A E Arnold.;J Arnout.;F De Cock.;D Collen.;M Verstraete.
来源: Circulation. 1992年85卷3期928-34页
Fibrin generation during and after therapy with alteplase may depend on the level of concomitant anticoagulation. The hypothesis that fibrinopeptide A (FPA) levels, as markers of ongoing in vivo fibrin formation, correlate with the angiographic and clinical outcome of thrombolysis is tested.
|